Aiming for protective T-cell responses: A focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials
Autor principal: | Hanke, T |
---|---|
Formato: | Journal article |
Publicado em: |
Taylor and Francis
2019
|
Registos relacionados
-
Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
Por: Ondondo, B, et al.
Publicado em: (2013) -
Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
Por: Ondondo, B, et al.
Publicado em: (2013) -
Optimizing Delivery of the HIVconsv Immunogen in Rhesus Macaques
Por: Rosario, M, et al.
Publicado em: (2011) -
Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques
Por: Borthwick, N, et al.
Publicado em: (2015) -
Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
Por: Hancock, G, et al.
Publicado em: (2017)